Yan Tang

Yan Tang

Auto-generated profile, based on publicly available information

Yan Tang

Brigham and Women’s Hospital 4 Department of Medicine Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MQMin Qiu
Min Qiu
YTYan Tang
Yan Tang
JCJinjin Chen
Jinjin Chen
RMRachel Muriph
Rachel Muriph
ZYZhongfeng Ye
Zhongfeng Ye
QXQiaobing Xu
Qiaobing Xu
Significance: The current application of messenger RNA (mRNA)-based technology has largely been confined to liver diseases because of the lack of a specific and efficient extrahepatic in vivo systemic mRNA delivery system. Here, we have developed a library of N-series lipid nanoparticles (LNPs) that could specifically regulate the protein composition of protein corona on the surface of LNPs, which allows specific delivery of mRNA to the lung. We further demonstrated that our lung-targeting LNP could effectively deliver mouse tuberous sclerosis complex 2 ( Tsc2 ) mRNA into TSC2-null cells and restore its function, resulting in enhanced control of tumor burden in a preclinical model of lymphangioleiomyomatosis, a destructive lung disease caused by loss-of-function mutations in the Tsc2 gene.

8 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LZLong Zhang
Long Zhang
CHCharbel S. Hobeika
Charbel S. Hobeika
DKDamir Khabibullin
Damir Khabibullin
DYDeyang Yu
Deyang Yu
HFHarilaos Filippakis
Harilaos Filippakis
EHElizabeth P Henske
Elizabeth P Henske
Chromophobe (Ch) renal cell carcinoma (RCC) arises from the intercalated cell in the distal nephron. There are no proven treatments for metastatic ChRCC. A distinguishing characteristic of ChRCC is strikingly high levels of reduced (GSH) and oxidized (GSSG) glutathione. Here, we demonstrate that ChRCC-derived cells exhibit higher sensitivity to ferroptotic inducers compared with clear-cell RCC. ChRCC-derived cells are critically dependent on cystine via the cystine/glutamate antiporter xCT to maintain high levels of glutathione, making them sensitive to inhibitors of cystine uptake and cyst(e)inase. Gamma-glutamyl transferase 1 (GGT1), a key enzyme in glutathione homeostasis, is markedly suppressed in ChRCC relative to normal kidney. Importantly, GGT1 overexpression inhibits the proliferation of ChRCC cells in vitro and in vivo, suppresses cystine uptake, and decreases levels of GSH and GSSG. Collectively, these data identify ferroptosis as a metabolic vulnerability in ChRCC, providing a potential avenue for targeted therapy for these distinctive tumors.

1 December 2019 in Chest
Verified
Journal Article
Closed access
YTYan Tang
Yan Tang
SESouheil El-Chemaly
Souheil El-Chemaly
ATAngelo Taveira-Dasilva
Angelo Taveira-Dasilva
HGHilary J. Goldberg
Hilary J. Goldberg
SBShefali Bagwe
Shefali Bagwe
EHElizabeth P. Henske
Elizabeth P. Henske

24 February 2026 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
EAElio Adib
Elio Adib
Amin NassarAmin Nassar
Amin Nassar
SASarah Abou Alaiwi
Sarah Abou Alaiwi
SBSylvan C. Baca
Sylvan C. Baca
THTimothy Hanlon
Timothy Hanlon
MFMatthew Freedman
Matthew Freedman
We generated 64 epigenomic datasets using chromatin immunoprecipitation with sequencing and assay for transposase-accessible chromatin sequencing profiling on 28 fresh bladder cancer specimens of luminal and basal-squamous expression subtypes. An integrated analysis of core regulatory circuitry, enhancer activity, and transcription factor (TF) expression specificity nominated 23 luminal-specific and 14 basal-squamous–specific candidate master TFs (MTF), including established regulators like FOXA1, PPARG, and GATA3 for luminal bladder cancer and TP63 for basal-squamous bladder cancer, as well as new basal-squamous MTF candidates, SNAI2 and CEBPB. GRHL2, a regulator of subtype differentiation, was identified as a common MTF to luminal and basal-squamous bladder cancers. Cis-regulatory elements were enriched up to 80-fold for bladder cancer risk variants. Keratinization pathways were enriched in genetically determined basal-squamous sites, whereas carcinogen glucuronidation pathways were enriched in luminal sites. Integrating germline variation and epigenomics through a cistrome-wide association study identified a new bladder cancer risk locus upstream of SPINK1 and linked 10 of 19 bladder cancer risk loci to regulatory elements from a 350,000-sample genome-wide association study. Implications: Overall, this integrative computational analysis provides comprehensive insights into the epigenomic underpinnings of bladder cancer subtypes, nominates candidate master regulators of cellular identity for future experimental validation, and reveals how regulatory elements harboring inherited germline variation may contribute to bladder cancer risk and biology.

19 June 2026
Verified
Other
Open access
PDF file
EAElio Adib
Elio Adib
Amin NassarAmin Nassar
Amin Nassar
SASarah Abou Alaiwi
Sarah Abou Alaiwi
SBSylvan C. Baca
Sylvan C. Baca
THTimothy Hanlon
Timothy Hanlon
MFMatthew Freedman
Matthew Freedman
Supplementary Figure S9. Overall survival in the bladder cancer TCGA cohort by UGT1A10 and SPINK1 expression (top vs. bottom quartiles shown).

19 June 2026
Verified
Other
Open access
EAElio Adib
Elio Adib
Amin NassarAmin Nassar
Amin Nassar
SASarah Abou Alaiwi
Sarah Abou Alaiwi
SBSylvan C. Baca
Sylvan C. Baca
THTimothy Hanlon
Timothy Hanlon
MFMatthew Freedman
Matthew Freedman
Supplementary Table S4. Top TFs by CaCTS score in basal-squamous and luminal BLCA samples.